NIH Funding Opportunities (Notices, PA, RFA)

Subscribe to NIH Funding Opportunities (Notices, PA, RFA) feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 1 hour 55 min ago

Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery

Wed, 2021-12-01 03:15
Notice NOT-AI-22-014 from the NIH Guide for Grants and Contracts

Notice of Early Expiration of PA-19-077, Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)"

Wed, 2021-12-01 03:15
Notice NOT-AI-22-009 from the NIH Guide for Grants and Contracts

Continuation or Revision of NIDCR Clinical Trial Implementation Cooperative Agreement (UH3 Clinical Trial Required)

Wed, 2021-12-01 02:08
Funding Opportunity PAR-22-068 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will accept applications for competing renewal or competitive revisions of ongoing clinical trials supported by the National Institute of Dental and Craniofacial Research (NIDCR). Extension of an ongoing clinical trial through a competing renewal application will be supported when there is need for additional time to complete the trial or when an extended period of follow-up is well justified to assess longer term outcomes. Competitive revisions will be supported when there is compelling justification for modifying the scope of the ongoing clinical trial. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact for the ongoing clinical trial for which they are planning a competing renewal or competitive revision prior to submitting an application to this FOA.

Request for Information on Proposed Updates and Long-Term Considerations for the NIH Genomic Data Sharing Policy

Tue, 2021-11-30 03:18
Notice NOT-OD-22-029 from the NIH Guide for Grants and Contracts

Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs

Tue, 2021-11-30 03:13
Notice NOT-DA-23-002 from the NIH Guide for Grants and Contracts

High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)

Tue, 2021-11-30 03:02
Funding Opportunity PAR-22-069 from the NIH Guide for Grants and Contracts. The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community.This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of the NIDDK.

Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology

Tue, 2021-11-30 02:52
Notice NOT-CA-22-003 from the NIH Guide for Grants and Contracts

Resource Networks for Protein Polymorphisms in Alzheimers Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed)

Mon, 2021-11-29 12:52
Funding Opportunity RFA-AG-22-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U24 Cooperative Agreement applications aiming to establish misfolded protein polymorphisms resource networks in the area of Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). The central goal of these resource networks is to standardize and distribute seed, oligomers, and fibrils to other investigators in order to clarify and improve the reproducibility of experiments in AD/ADRD. Establishing standards, understanding the pathological roles of these protein polymorphs, and using newly developed analytic tools to address the direct correlation between patient-to-patient variations in A, ?-synuclein, and tau polymorphs are the long-term goals of the resource networks supported by this FOA.

Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity

Mon, 2021-11-29 10:55
Notice NOT-AI-21-082 from the NIH Guide for Grants and Contracts

NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)

Mon, 2021-11-29 10:52
Funding Opportunity PAR-22-065 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications for support of national or regional resources that will provide access to state-of-the-art facilities, equipment, technologies, research tools, software, and/or service to a substantial user base at institutions across multiple states (regional) or the country (national). These resources should already be established, although new resources formed through consolidation of multiple local or regional facilities are also eligible. They should be poised to achieve or already have achieved significant economies of scale and should be able to significantly increase access to the supported technologies or services for researchers across one or more regions or the country. Major new research and development efforts should not be included. For this FOA, a resource is defined as an activity that provides research capabilities and expertise to a large number of investigators and is available to any qualified investigator as a service. The intent is to provide access to investigators without regard to the particular biomedical focus of their research, but not to duplicate or replace resources supported by other NIH Institutes and Centers (ICs) or host institutions. Only those resources whose technical capabilities fall within the program areas supported by NIGMS will be supported. It is expected that the resource will be maintained or upgraded to current best practices, make its capability and availability known to the biomedical research community through outreach activities, and provide user training and support. Stand-alone data resources and databases are not eligible for funding through this FOA. This FOA is limited to applications requesting support for resources that have been developed through previous NIGMS funding.

Notice of Change to Key Dates for PAR-19-261, "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)"

Mon, 2021-11-29 10:28
Notice NOT-HD-21-054 from the NIH Guide for Grants and Contracts

Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed)

Mon, 2021-11-29 10:22
Funding Opportunity RFA-DK-21-032 from the NIH Guide for Grants and Contracts. The overall goal of the Fostering Research With Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the benign urologic research community. FORWARD Urology Centers will support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising junior investigators and/or researchers new to the field of benign urologic research. It is expected that the Research Project Team will generate data to support one or more follow-on independent grant applications (e.g., R01s). The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Team to help ensure the research aims are met and to aid them in their successful integration into the broader benign urologic research field. To facilitate these goals, the Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDKs CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program.

National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U2C - Clinical Trial Not Allowed)

Mon, 2021-11-29 10:15
Funding Opportunity RFA-DK-21-027 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications for National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD). The Centers will provide complex metabolic, physiologic and behavioral phenotyping and consulting services to characterize living mouse models on a fair fee-for-service basis. Tests that do not require living animals will not be supported by this initiative. MPMODs may also provide special mouse models for study at the Center or for distribution, such as mice that have undergone bariatric surgery or implanted catheters. Services are provided with equal priority to investigators inside and outside the home institution, at similar cost, to study the heterogeneity, pathogenesis, and metabolic and physiologic consequences of diabetes and obesity. The MPMOD Centers will work together as a consortium, supported by a Coordinating Unit, to improve access to high quality consultation and phenotyping for metabolic disease research conducted in mice; establish outreach/advertising to potential clients; find ways to enable underrepresented PIs and those from small research institutions to produce outstanding results and better compete for funding; and be synergistic and cost-effective, includingdeveloping common test protocols and eliminating overlap where appropriate.

Coordinating Unit for the National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U24 - Clinical Trial Not Allowed)

Mon, 2021-11-29 10:14
Funding Opportunity RFA-DK-21-035 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish a Coordinating Unit (CU) to support the National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD). MPMOD Centers, solicited via RFA DK-21-027,will ?provide complex metabolic, physiologic and behavioral phenotyping and consulting services to characterize living mouse models on a fair fee-for-service basis. Services are provided with equal priority to investigators inside and outside the home institution, at similar cost, to study the heterogeneity, pathogenesis, and metabolic and physiologic consequences of diabetes and obesity. The MPMOD Centers will work together as a consortium, supported by the Coordinating Unit, to improve access to high quality consultation and phenotyping for metabolic disease research conducted in mice. An important goal of this consortium will be to enable underrepresented PIs and those from small research institutions that traditionally have not received significant research funding and/or have historically served under-represented populations to produce outstanding results and better compete for funding.

Pages